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Abbreviations in alphabetical order 
1
st
 WIT, first warm ischemia time (time from stop circulation till aortic cold perfusion) 
ARDS, acute respiratory distress syndrome 
CIT, cold ischemia time 
DBD, donation after brain death 
DCD, donation after circulatory death 
DRI, donor risk index 
ELIAC, Eurotransplant Liver Intestine Advisory Committee 
ET, Eurotransplant 
ET-DRI, Eurotransplant donor risk index 
GGT, gamma glutamyl transpeptidase 
HR, hazard ratio 
LT, liver transplantation 
ITBL, ischemic-type biliary lesions (or NAS, non-anastomotic strictures) 
MELD, model for end-stage liver disease 
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MOF, multi organ failure 
NAS, non-anastomotic strictures 
PNF, primary non-function 
SD, standard deviation 
SRTR, Scientific Registry of Transplant Recipients 
UNOS, United Network for Organ Sharing; 
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Abstract 
Donation after circulatory death (DCD) liver transplantation (LT) may imply a risk for decreased graft 
survival, caused by post-transplantation complications such as primary non-function or ischemic-
type biliary lesions. However, similar survival for DCD and donation after brain death (DBD) LT has 
been reported. Objective of this study is to determine long-term outcome of DCD LT in the 
Eurotransplant region corrected for Eurotransplant donor risk index (ET-DRI). Transplants performed 
in Belgium and The Netherlands (1.1.2003 - 31.12.2007) in adult recipients were included. Graft 
failure was defined as either date of recipient death or retransplantation; death un-censured graft 
survival. Mean follow-up was 7.2 years. In total 126 DCD and 1264 DBD LT’s were performed. 
Kaplan-Meier survival analyses showed different graft survival for respectively DBD and DCD at one 
(78% vs. 75%, p=0.71), five (66% vs. 54%, p=0.02) and ten (47% vs. 44%, p=0.55) years (Log Rank 
p=0.038). Although there was an overall significant difference, the survival curves almost reach each 
other after 10 years, most probably caused by lower other risk factors in DCD livers. Patient survival 
was not significantly different (p=0.59). Multivariate Cox-regression analysis showed a HR 1.7 
(p<0.001) for DCD (corrected for ET-DRI and recipient factors). First warm ischemia time (1
st
 WIT) 
over 25 minutes was associated with a lower graft survival in univariate analysis of all DCD 
transplants (p=0.002). Conclusions: DCD LT has an increased risk for diminished graft survival 
compared to DBD. There was no significant difference in patient survival. DCD allografts with a 1
st
 
WIT>25 minutes give an increased risk for decreased graft survival. 
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Introduction 
Donation after circulatory death (DCD) is known to be one of the most important donor risk factors 
for worse outcome after liver transplantation (LT). Previous studies have reported a hazard ratio 
(HR) of 1.51 in the United Network for Organ Sharing (UNOS) (1) and 1.71 in Eurotransplant (ET) 
(2). Post-transplant complications such as ischemic-type biliary lesions (ITBL) and primary non-
function (PNF) occur more often, resulting in higher retransplantation rates. (3-6) Still, similar results 
for grafts from controlled DCD donors compared with grafts from donation after brain death (DBD) 
donors have been reported from the initial series from The Netherlands, with a higher 
retransplantation rate in the DCD-group due to biliary problems, (7) whereas a large study with data 
from the Scientific Registry of Transplant Recipients (SRTR), investigating DCD and DBD outcome, 
found decreased survival for the DCD group. (8) This indicates that the use of controlled DCD 
donors could be a justified alternative source for livers next to DBD donors, when bearing this 
additional risk in mind. Some studies even reported equally good early outcome for extended criteria 
DCD grafts as compared to standard DCD grafts. (9) The same conclusions came from several 
(recent) reports from Belgium (10-12) and The Netherlands (7,13). 
Studies investigating risk factors in DCD liver transplantation found certain donor factors, such as 
age, weight, cold and warm ischemia time to be significantly associated with graft failure after DCD 
liver transplantation. (14,15) Since the DCD procedure itself leads to a certain first warm ischemia 
time (1
st
 WIT), which is potentially harmful to the liver, only donors with little other risk factors are 
being evaluated and stricter criteria for donation are used compared to DBD donors. Furthermore, 
patients can be selected by MELD score as recipient in order to acquire the optimal result or highest 
benefit. (16-18) Unfortunately, there are few studies investigating the long-term effect of DCD on 
outcome after LT. 
 
The objective of this study is to investigate the long-term outcome for DCD liver transplantation 
within the ET region and evaluate the effect of DCD versus DBD, adjusted for the ET donor risk 
index (ET-DRI) and recipient risk factors.  
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Patients and Methods 
This study is a retrospective analysis of all deceased donor liver transplants performed in Belgium 
and The Netherlands into adult (≥18 years) recipients during the period from January 1
st
 2003 till 
December 31
st
 2007. Transplants performed in countries that did not perform DCD transplants 
(Austria, Croatia, Germany, Luxemburg and Slovenia) in this dataset (N=4549) and transplants 
performed with liver allografts from outside Eurotransplant (N=89) were excluded. Follow-up data of 
all 1390 liver transplants were obtained from the Eurotransplant database in March 2015, with 
consent of the Eurotransplant Liver Intestine Advisory Committee (ELIAC). All data were 
anonymized for transplant center and country. 
 
Data selection 
In the study period DCD liver transplants were only performed in two Eurotransplant countries 
(Belgium and The Netherlands) and therefore only the transplants performed in these countries were 
used in the analysis (N=1390). There were 98 missing values (7.1%) in the follow-up data (patients 
lost to follow-up). The remaining 1292 transplants were used in the survival analysis. The DRI (1) 
and ET-DRI (2) were calculated for all donors when all factors were available. As race is not 
registered in the Eurotransplant database, all donors were regarded as reference (Caucasian) when 
calculating the DRI. Since ‘national sharing’ within UNOS is different than ‘national sharing’ within 
Eurotransplant, all countries, except for Germany, were regarded as one donor region within 
Eurotransplant. National sharing was considered as extra-regional sharing, meaning sharing within 
the whole of Eurotransplant. Due to missing cold ischemia times (CIT) or most recent gamma 
glutamyl transpeptidase (GGT), it was not possible to calculate the DRI for 275 donors and the ET-
DRI for 290 donors; these transplants were therefore not included in the analysis with DRI/ET-DRI. 
 
Statistical analysis 
Graft survival (death un-censured) was defined as the period from date of transplantation until date 
of retransplantation or recipient death, whichever occurred first. There is no ‘general agreement’ 
within the ET region or between the ET member states on strategies for retransplantation, leading to 
a different situation for each individual transplant center. Some centers may treat biliary 
complications with interventions whereas other centers may choose for a retransplantation faster. 
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First warm ischemia time was defined as time from stop circulation till start of cold organ perfusion. 
For the analysis of first warm ischemia time, five subgroups were created: <10 minutes, 10-15 
minutes, 16-20 minutes, 21-25 minutes and >25 minutes. Clinical characteristics were summarized 
in mean and standard deviation (SD) for continuous variables or number and percentage for 
categorical factors. Comparison between groups was done using Chi-square (categorical factors) or 
Student’s t-test (continuous factors). Survival analyses were performed using Kaplan-Meier survival 
curves and multivariate analyses were performed using Cox regression models. For all analyses a 
Wald p-value of p<0.05 was considered significant. Statistical analyses were performed with SPSS, 
version 23.0. 
 
Results 
In total 126 DCD and 1264 DBD liver transplants were performed in the study period, with a mean 
follow-up of 7.2 years. Donor and transplant characteristics of the two groups are displayed in  
Table 1. Significant differences between DCD and DBD were lower donor age (41 years vs. 47 
years, p<0.001), less cerebrovascular accidents in the DCD-group 41% vs. 59% (p<0.001), no split 
liver in the DCD-group (p=0.02), mostly local and regional allocation (p<0.001) and lower CIT in the 
DCD-group (7.2h vs. 8.9h, p<0.001). There was a higher percentage of rescue allocation in the 
DCD-group (26% vs. 12%, p<0.001), which was the only other factor with increased risk in the DCD-
group.  
 
Mean DRI and ET-DRI of DCD donors were higher as compared to the DBD-group, respectively DRI 
2.0 vs. 1.6 (p<0.001) and ET-DRI 2.1 versus 1.7 (p<0.001). When the factor DCD was excluded 
from the (ET-) DRI calculation, the mean values in the DCD-group were much lower compared to the 
DBD-group: DRI 1.3 vs. 1.6 (p<0.001) and ET-DRI 1.4 vs. 1.7 (p<0.001). 
Recipient factors are displayed in Table 1. Recipients transplanted with a DCD liver allograft were 
slightly older, however not significantly (p=0.42), more often male (p=0.02), had a significant lower 
mean MELD score (16 vs. 20, p<0.001) and a lower percentage of high urgent transplantation (5% 
vs. 15%, p=0.002). DCD allografts were transplanted significantly less often in retransplantation 
candidates (5% vs. 15%, p=0.002). 
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Long-term outcome of DCD vs. DBD 
Kaplan-Meier survival curves showed different graft survival rates for DCD versus DBD (Log Rank 
p=0.038) (Figure 1 and Table 2), meaning there were more added life-years / grafts last longer after 
transplantation of a DBD liver compared to a DCD liver (reflected in area under the curve). Specific 
graft survival at one (75% vs. 78%, p=0.71), five (54% vs. 66%, p=0.02) and ten years (44% vs. 
47%, p=0.55) showed that the differences in graft survival increased in the first 5 years and 
decreased in the following years, leveling out at around 10 years post-transplantation. 
Univariate Cox regression analysis gave a hazard ratio (HR) of 1.31 (95% CI 1.01-1.69, p=0.04) for 
DCD compared to DBD. There was no significant difference in patient survival between DCD and 
DBD at the previously named time points (p=0.59; Table 2). Interestingly, patient death was not 
significantly different, but there was a significantly higher chance for retransplantation after DCD LT. 
Reasons for patient death or retransplantation are shown in Table 3. Thrombosis was a relatively 
more frequent cause of retransplantation after DBD LT (1.7% vs. 0.8%), whereas the DCD recipients 
had a higher percentage of PNF, 3.2% vs. 0.7%, and non-anastomotic strictures (NAS) 6.3% vs. 
0.6% (p=0.002). 
 
Multivariate analysis 
Multivariate Cox regression analyses of the ‘DCD factor’ in relation to graft survival, corrected for 
other factors in the DRI, ET-DRI and all available recipient factors (age, MELD, high urgent status, 
cause of end-stage liver disease, retransplantation status), gave a HR of respectively 1.86 (95% CI 
1.38-2.52, p<0.001) (for DRI factors) and 1.81 (95% CI 1.33-2.47, p<0.001) (for ET-DRI factors). 
When the DCD was corrected for the calculated DRI and ET-DRI, (calculated without the factor 
DCD) and recipient factors, it remained significantly associated with graft survival with a HR of 
respectively 1.73 (95% CI 1.30-2.30, p<0.001) (DRI) and 1.70 (95% CI 1.27-2.25, p<0.001) (ET-
DRI). This also confirms the strong correlation between the DRI, ET-DRI and DCD. 
 
Sub analysis of first warm ischemia time 
Next, a sub-analysis of the DCD-group was performed (N=126) to investigate the influence of the 1
st
 
WIT. Mean 1
st
 WIT was 14 (range 4-38) minutes. Kaplan-Meier survival analysis of the 1
st
 WIT 
divided into five categories (see Methods) not significantly associated with graft survival (log rank 
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test p=0.12), but showed the impact of 1
st
 WIT>25 minutes (Table 4). When performing an univariate 
analysis with the cut-off at 25 minutes, there was a significant correlation with graft survival (HR3.11, 
95% CI 1.24-7.79, p=0.02). Multivariate Cox regression analysis of this factor, corrected for the ET-
DRI, showed a trend towards a significant correlation with graft survival when divided into five 
categories (p=0.11) and when using a cutoff of 25 minutes it was significant (HR3.53, 95% CI 1.38-
9.04, p=0.009). Figure 2 shows the Kaplan Meier survival curve for patients that were transplanted 
with a liver allograft that sustained >25 minutes of WIT compared with grafts with a WIT≤25 minutes. 
 
Discussion 
This study investigated the risk of DCD liver transplantation within two countries belonging to the ET 
region, Belgium and The Netherlands, with long-term follow-up and aimed to adjust the increased 
risk of the ‘factor DCD’ by using the DRI and ET-DRI. 
 
The results show that it seems that by adequate selection of DCD allografts the additional risk of a 
DCD procedure can be kept to a minimum. This is actually clinical practice, because when excluding 
DCD as a factor from the DRI and ET-DRI, the risk indices became much lower for the DCD-group 
(DRI 1.3 and ET-DRI 1.4) as compared to the mean (ET-)DRI of the DBD group. This indicates that 
DCD donors indeed have better ‘other’ donor characteristics, such as lower donor age, less CVA as 
cause of death, lower cold ischemia time and no split liver donation. 
The recipient characteristics between the DBD and DCD group differed in relation to recipient MELD 
score, percentage of HU-status and repeated transplantation; DCD recipients were in better 
condition. The results also show that there seems to have been an increased frequency of infections 
in the DCD group (6.3% vs. 3.8% in the DBD group). We tried to look for a possible relation with the 
occurrence of biliary complications, however it was impossible to distract any clear correlation from 
the provided data of the 11 centers. 
In the Kaplan-Meier curve graft survival at five years was worse in the DCD group (Figure 1), but this 
difference leveled out after ten years follow-up. Patient survival rates were not significantly different 
in DCD and DBD grafts at any time in follow-up (Table 2). This means that there is a higher chance 
for graft failure and subsequent retransplantation within the first five years after DCD LT, probably 
explained by the higher incidence of biliary complications (ITBL/NAS) in DCD grafts. (15,19) After 
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five years the failure risk for DCD allografts is lower when compared to DBD allografts, which might 
be explained in turn by the younger donor age and better condition of recipients at the time of LT. As 
transplant physicians take patients disease and current situation into account when accepting 
organs, they might decide to accept or decline a DCD liver allograft, knowing the potential risks of 
this allograft after LT. Also the consent of the patient is something that could play a role in the 
acceptance of such a liver allograft. 
 
When correcting for recipient factors and ET-DRI in the multivariate analysis the factor DCD is a very 
significant risk factor with a high hazard ratio (HR 1.7, p<0.001). This study is the first to show this 
additional risk by correcting for other factors that could influence outcome (donor, transplant and 
recipient factors) by using the ET-DRI. A recent study by Singhal et al. found similar results in a 
matched controlled analysis with data of the SRTR database: DCD donors were younger, had 
shorter CIT’s and recipients had lower MELD scores. Another finding in that study was the 
significantly higher associated costs and a higher re-admission rate for DCD recipients, (20) 
comparable to data from the Netherlands. (21) The difference in graft survival as compared to the 
earlier study by Dubbeld et al. (7) might be due to the acceptance of increasing risk factors when 
getting more acquainted with the DCD procedure over time and a larger sample size. 
 
This study has several limitations such as the retrospective study design and the recipient selection 
bias, as this selection was already done by the recipient center. However, we minimized this effect 
by correcting for donor and recipient factors. Another limitation is the selected endpoint of combined 
patient and graft survival (death un-censured graft survival) as only outcome parameter. In order to 
do a good interpretation of the problems after DCD liver transplantation biliary complications such as 
ITBL (or NAS) should also be taken into account as an end-point. Unfortunately these data are not 
standard registered in the ET database. Nevertheless, cases of severe biliary damage will eventually 
lead to retransplantation, which was taken as an endpoint in this study. Another limitation was the 
fact that in 275 cases the DRI and in 290 the ET-DRI could not be calculated due to missing CIT or 
GGT in the ET database. Lastly, the survival curves almost reach each other at ten years, but the 
percentage of patients in the analysis at ten years follow-up was lower than ten percent of the total 
number of patients in that subgroup. 
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The factor 1
st
 WIT was demonstrated to have an important impact on outcome in DCD LT. Donor 
WIT above the cut-off value of 25 minutes significantly correlated with worse outcome (p=0.011). 
When analyzing this factor more in detail by creating five different WIT groups there was no 
significant correlation with graft survival, but there was a clearly lower graft survival if the 1
st
 WIT 
encompassed 25 minutes (graft survival of 17%). Although the risk of increased 1
st
 WIT has already 
been described in previous studies in relation to the higher chance for primary non-function, graft 
dysfunction or biliary strictures (10,22), this study shows this risk after LT when correcting for the ET-
DRI in the multivariate analysis. Accepting of a liver graft with 1
st
 WIT above 25 min, should probably 
only be considered for specific cases, and only if other risk factors are kept low (donor age, CIT, 
etc.). Another option could be to look for strategies to decrease the risk of the 1
st
 WIT to exceed 25 
minutes, for example by withdrawal of ventilatory support in the operating room as is standard 
protocol in Belgium. Within The Netherlands the standard procedure is to perform the withdrawal of 
ventilatory support in the intensive care unit (ICU). After the death is declared at the cessation of 
circulation, there is a mandatory no-touch period of 5 minutes, in which period the donor may be 
transported to the OR. In Belgium this period varies from 2 till 4 minutes (10,23), leading to a 
minimal 1
st
 WIT of 2-5 minutes. Practical issues such as transport of the donor from ICU to the 
operating room and preparation for the organ perfusion might lead to additional 1
st
 WIT, especially in 
The Netherlands. Obviously there are selected cases in which the perfusion exceeds the preferred 
time limit of 25 minutes, but as our results show, this only occurs incidentally. Technical issues (or 
lack of) do not seem to be related to these sometimes ‘longer’ 1
st
 WIT periods since all involved 
surgeons in The Netherlands and Belgium are specifically trained in and certified for multi-organ 
donation procedures.  
 
In the ET region the definition of the 1
st
 WIT is defined as: ‘time from cardiac arrest until perfusion of 
the donor’ (ET manual, Ch. 9). This is a clear agreement made by the ET countries. The problem is 
however that different definitions are used worldwide and that the more common definition is the 
time period from withdrawal of ventilation till start of cold organ perfusion. This issue has been 
already addressed previously. (10,23) Nevertheless, a clear and unambiguous definition remains 
important and should be looked at more carefully, as was for example done by Taner et al. in a 
recent UK study. (24,25) Unfortunately clinical donor data with regard to the withdrawal of life 
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support procedure (e.g. oxygen saturation or mean arterial pressure values) were not recorded in 
this ET dataset and could unfortunately not be investigated. 
 
Within the Netherlands there is a strict protocol for selecting DCD donors: ‘the Dutch protocol for 
organ donation’. This protocol upholds certain criteria for DCD liver allograft donation in The 
Netherlands, such as maximum donor age of 60 years. (26) In 2013 the percentage of DCD liver 
transplantation was 22% in Belgium and even as high as 38% in the Netherlands. (27) Although the 
DCD procedure holds certain risks, such as increased rates of biliary complications, hepatic artery 
stenosis or decreased outcome, it provides a valuable source for donor liver allografts in this time of 
organ scarcity. Univariate graft survival between the two groups was comparable, but significantly 
better in the DBD group. When looking at other risk factors such as donor age and CIT for DCD 
donors, almost equally good results can be achieved. This was advised in the recent British 
Transplantation Society guidelines for DCD transplantation. (28) Nevertheless, the possibly poorer 
quality of life of patients with biliary strictures should also be taken into account. 
 
The risk of DCD LT is well known, so several measures to improve results are proposed such as the 
limitation of the 1
st
 WIT and CIT (which are modifiable risk factors). There is also a need to 
implement innovative strategies to ameliorate graft quality, such as donor preconditioning using in 
situ reconditioning (with the use of extracorporeal machine oxygenation (ECMO)) or post 
procurement reconditioning by use of machine perfusion. (29) At the time of the organ offer, the 1
st
 
WIT is mostly not known since the DCD procedure is yet to start. After the organ recovery the 1
st
 
WIT is known and one of the factors that could be influenced to mitigate for a longer 1
st
 WIT is the 
CIT. Solutions for shortening this CIT is by local or national allocation, which is currently the case in 
Belgium and The Netherlands. Another factor that could correct for a potentially longer 1
st
 WIT is 
lower donor age. As shown in this study, the ET-DRI (without the factor DCD) is significantly lower in 
DCD donors, with age being a major factor in the ET-DRI calculation and also being significantly 
lower as compared to DBD donors. Nevertheless, recent studies did not find any difference in 
outcome for younger or older DCD donors and concluded that a DCD donor should not be discarded 
purely based on age, since increased donor age did not contribute to graft failure after DCD liver 
transplantation. (12,30) 
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In conclusion, this is the first European study to evaluate long-term outcome of LT using circulatory 
death donors. DCD is confirmed to be a risk factor causing a significantly decreased graft survival 
after LT in Belgium and The Netherlands (HR 1.7, p<0.001). This difference in graft survival peaks at 
five years, but seems to flatten out afterwards. Patient survival did not significantly differ and this 
should therefore encourage the use of DCD liver allografts. 
Altogether, recipients of a DCD liver have a higher risk of graft loss within the first five years after 
transplantation (due to biliary complications such as ITBL), but if this is not the case, the graft 
survival tends to be better than with a DBD liver graft, probably due to the lower donor age and on 
average the better condition of the recipient at time of transplantation. First warm ischemia time 
longer than 25 minutes has a significant risk for decreased outcome after DCD liver transplantation 
and when exceeding 25 minutes the majority of transplanted DCD livers failed. 
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Figure legends 
 
Figure 1: 
Long-term graft survival for DCD and DBD transplantations (log rank test p=0.038) 
- Green line: DCD transplantations 
- Blue line: DBD transplantations 
 
Figure 2: 
Long-term graft survival for first warm ischemia time categories (log rank test p=0.011) 
- Green line: 1
st
 WIT >25 minutes 
- Blue line: 1
st
 WIT ≤25 minutes 
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Table 1: donor, transplant and recipient characteristics for DBD (N=1264) and DCD (N=126) 
  DBD   DCD   
Factor N (%)   N (%) p-value 
Female donor 597 (47) 49 (39) 0.07 
Cause of death <0.001 
    CVA 749 (59) 51 (41) 
    Trauma 406 (32) 38 (30) 
    Anoxia 61 (5) 22 (18) 
    Other 48 (4) 15 (12) 
Split liver 52 (4.1) 0 0.02 
Allocation <0.001 
    Local 261 (21) 52 (41) 
    Regional 617 (49) 68 (54) 
    Extra-regional 386 (31) 6 (5) 
Rescue allocation 157 (12) 33 (26) <0.001 
Perfusion fluid 
    UW 614 (49) 58 (46) 
    HTK 559 (44) 58 (46) 
   Other 91 (7.2) 10 (8) 0.85 
  Mean (SD)   Mean (SD)   
Donor age (years) 46.8 (15.9)   41.2 (14.1) <0.001 
Height 173 (9.5) 175 (9.5) 0.049 
BMI 24.6 (3.6) 24.3 (3.6) 0.47 
GGT (U/L) 53 (82) 50 (69) 0.67 
1st warm ischemia time (min) n/a 13.2 (7.3) 
Cold ischemia time (hours) 8.9 (2.8) 7.2 (2.1) <0.001 
DRI 1.58 (0.39) 2.00 (0.38) <0.001 
    without factor DCD* n/a  1.33 (0.25)  
ET-DRI 
    without factor DCD* 
1.65 (0.40) 
n/a   
2.13 (0.43) 
1.44 (0.29) 
<0.001 
 
 
DBD   DCD   
Factor N (%)   N (%) p-value 
Recipient sex 0.02  
    Male 810 (64) 94 (75) 
    Female 454 (36) 32 (25) 
High urgent 184 (15) 6 (4.8) 0.002 
Repeated transplant 192 (15) 6 (4.8) 0.001 
  Mean (SD)   Mean (SD)   
Recipient age (years) 51.6 (11.8)   53.0 (11.5) 0.42 
MELD 19.5 (9.9)   16.2 (7.8) 0.004 
*not applicable since this only applies for DCD donors; value is equal to value above (DRI 1.58, ET-DRI 1.65)
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Table 2: Death un-censured graft survival and patient survival after DBD and DCD liver 
transplantation 
 
    Graft survival (95% Confidence Interval; p=0.038) 
N (%) 1 year 5 years 10 years 
DBD 1168 (90) 77.7 (75.3 – 80.1) 65.6 (62.8 – 68.4) 47.3 (43.1 – 51.5) 
DCD 124 (10) 74.8 (67.0 – 82.6) 54.4 (45.4 – 63.4) 44.2 (34.6 – 53.8) 
     
  Patient Survival (95% Confidence Interval; p=0.59) 
DBD 1174 (90) 82.8 (80.6 – 85.0) 71.4 (68.6 – 74.2) 52.6 (48.4 – 56.8) 
DCD 124 (10) 87.8 (81.8 – 93.8) 68.1 (59.5 – 76.7) 55.9 (45.9 – 65.9) 
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Table 3 causes of death or retransplantation for DBD and DCD liver transplants 
 
 
  
DBD 
N=1264   
DCD 
N=126 p-value* 
Causes of graft loss N (%) N (%) 
Death 424 (34)   48 (38) 0.83 
  MOF/ARDS/sepsis 79 (6.3) 8 (6.3) 
  Infection 48 (3.8) 8 (6.3) 
  Cardiac 31 (2.5) 3 (2.4) 
  Malignant 98 (7.8) 13 (10) 
  Other 115 (9.1) 10 (7.9) 
  Unknown 53 (4.2) 6 (4.8) 
Retransplantation 73 (5.8)   18 (14) 0.002 
  Thrombosis 22 (1.7) 1 (0.8) 
  PNF 9 (0.7) 4 (3.2) 
  NAS 7 (0.6) 8 (6.3) 
  Rejection 5 (0.4) - 
  Other 8 (0.6) 3 (2.4) 
  Unknown 22 (1.7)   2 (1.6)   
*p-value of chi-square analysis of sub-groups in cause of death or cause of retransplantation 
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Table 4: Kaplan-Meier survival analysis of warm ischemia time categories (N=123, p=0.12) 
 
  
 
  
 
   
Warm ischemia time N (%)   5-years graft survival HR (95% CI) 
<10 minutes 34 (28) 56% Ref. 
10-15 minutes 40 (33) 58% 0.83 (0.44-1.55) 
16-20 minutes 28 (23) 61% 0.86 (0.43-1.72) 
21-25 minutes 15 (12) 43% 1.18 (0.52-2.70) 
>25 minutes 6 (5) 17% 2.87 (1.06-7.73) 
* 3 missing values out of 126 DCD transplants 
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Long-term graft survival for DCD and DBD transplantations (log rank test p=0.038)  
- Green line: DCD transplantations  
- Blue line: DBD transplantations  
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Long-term graft survival for first warm ischemia time categories (log rank test p=0.011)  
- Green line: 1st WIT >25 minutes  
- Blue line: 1st WIT ≤25 minutes  
254x190mm (300 x 300 DPI)  
 
 
Page 22 of 22
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
